Literature DB >> 22995540

Contraception technology: past, present and future.

Regine Sitruk-Ware1, Anita Nath, Daniel R Mishell.   

Abstract

Steady progress in contraception research has been achieved over the past 50 years. Hormonal and nonhormonal modern contraceptives have improved women's lives by reducing different health conditions that contributed to considerable morbidity. However, the contraceptives available today are not suitable to all users, and the need to expand contraceptive choices still exists. Novel products such as new implants, contraceptive vaginal rings, transdermal patches and newer combinations of oral contraceptives have recently been introduced in family planning programs, and hormonal contraception is widely used for spacing and limiting births. Concerns over the adverse effects of hormonal contraceptives have led to research and development of new combinations with improved metabolic profile. Recent developments include use of natural compounds such as estradiol and estradiol valerate with the hope to decrease thrombotic risk, in combination with newer progestins derived from the progesterone structure or from spirolactone, in order to avoid the androgenic effects. Progesterone antagonists and progesterone receptor modulators are highly effective in blocking ovulation and preventing follicular rupture and are undergoing investigations in the form of oral pills and in semi-long-acting delivery systems. Future developments also include the combination of a contraceptive with an antiretroviral agent for dual contraception and protection against sexually transmitted diseases, to be used before intercourse or on demand, as well as for continuous use in dual-protection rings. Although clinical trials of male contraception have reflected promising results, limited involvement of industry in that area of research has decreased the likelihood of having a male method available in the current decade. Development of nonhormonal methods is still at an early stage of research, with the identification of specific targets within the reproductive system in ovaries and testes, as well as interactions between spermatozoa and ova. It is hoped that the introduction of new methods with additional health benefits would help women and couples with unmet needs to obtain access to a wider range of contraceptives with improved acceptability.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22995540      PMCID: PMC3530627          DOI: 10.1016/j.contraception.2012.08.002

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  95 in total

1.  Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.

Authors:  Hans-Joachim Ahrendt; Israel Nisand; Carlo Bastianelli; Maria Angeles Gómez; Kristina Gemzell-Danielsson; Wolfgang Urdl; Birgit Karskov; Luc Oeyen; Johannes Bitzer; Geert Page; Ian Milsom
Journal:  Contraception       Date:  2006-09-27       Impact factor: 3.375

2.  Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables.

Authors:  Mandana Rad; Cornelis Kluft; Joël Ménard; Jacobus Burggraaf; Marieke L de Kam; Piet Meijer; Irving Sivin; Regine L Sitruk-Ware
Journal:  Am J Obstet Gynecol       Date:  2006-03-20       Impact factor: 8.661

3.  Comparison of pharmacodynamic properties of various estrogen formulations.

Authors:  C A Mashchak; R A Lobo; R Dozono-Takano; P Eggena; R M Nakamura; P F Brenner; D R Mishell
Journal:  Am J Obstet Gynecol       Date:  1982-11-01       Impact factor: 8.661

4.  Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial.

Authors:  Jeffrey T Jensen; Susanne Parke; Uwe Mellinger; Andrea Machlitt; Ian S Fraser
Journal:  Obstet Gynecol       Date:  2011-04       Impact factor: 7.661

5.  Protein kinase B/Akt phosphorylation of PDE3A and its role in mammalian oocyte maturation.

Authors:  Seung Jin Han; Sergio Vaccari; Taku Nedachi; Carsten B Andersen; Kristina S Kovacina; Richard A Roth; Marco Conti
Journal:  EMBO J       Date:  2006-11-23       Impact factor: 11.598

6.  Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women.

Authors:  Vivian Brache; Regine Sitruk-Ware; Alistair Williams; Diana Blithe; Horacio Croxatto; Narender Kumar; Sushma Kumar; Yun-Yen Tsong; Irving Sivin; Anita Nath; Heather Sussman; Leila Cochon; Maria Jose Miranda; Verónica Reyes; Anibal Faundes; Daniel Mishell
Journal:  Contraception       Date:  2011-12-15       Impact factor: 3.375

7.  Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trial.

Authors:  Kurt T Barnhart; Michael J Rosenberg; H Trent MacKay; Diana L Blithe; Jim Higgins; Terri Walsh; Livia Wan; Michael Thomas; Mitchell D Creinin; Carolyn Westhoff; William Schlaff; David F Archer; Charletta Ayers; Andrew Kaunitz; Sutapa Das; Thomas R Moench
Journal:  Obstet Gynecol       Date:  2007-09       Impact factor: 7.661

Review 8.  Nestorone: clinical applications for contraception and HRT.

Authors:  Regine Sitruk-Ware; Margaret Small; Narender Kumar; Yun-Yen Tsong; Kalyan Sundaram; Theodore Jackanicz
Journal:  Steroids       Date:  2003-11       Impact factor: 2.668

9.  Effect of a single vaginal administration of levonorgestrel in Carraguard gel on the ovulatory process: a potential candidate for "dual protection" emergency contraception.

Authors:  Vivian Brache; Horacio Croxatto; Regine Sitruk-Ware; Robin Maguire; Juan Carlos Montero; Narender Kumar; Ana Maria Salvatierra; Ana Sofia Tejada; Leila Cochón; María Luisa Forcelledo; Pekka Lahteenmaki; Francisco Alvarez; Anibal Faundes
Journal:  Contraception       Date:  2007-06-13       Impact factor: 3.375

10.  A new combination of testosterone and nestorone transdermal gels for male hormonal contraception.

Authors:  Niloufar Ilani; Mara Y Roth; John K Amory; Ronald S Swerdloff; Clint Dart; Stephanie T Page; William J Bremner; Regine Sitruk-Ware; Narender Kumar; Diana L Blithe; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2012-07-12       Impact factor: 5.958

View more
  37 in total

Review 1.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

Review 2.  Ovarian manipulation in ART: going beyond physiological standards to provide best clinical outcomes.

Authors:  Israel Ortega; Juan A García-Velasco; Antonio Pellicer
Journal:  J Assist Reprod Genet       Date:  2018-07-28       Impact factor: 3.412

Review 3.  Biomaterials and Contraception: Promises and Pitfalls.

Authors:  Isabella Claure; Deborah Anderson; Catherine M Klapperich; Wendy Kuohung; Joyce Y Wong
Journal:  Ann Biomed Eng       Date:  2019-11-07       Impact factor: 3.934

4.  The toxicological effect of Ruta graveolens extract in Siamese fighting fish: a behavioral and histopathological approach.

Authors:  Mohammad Navid Forsatkar; Mohammad Ali Nematollahi; Culum Brown
Journal:  Ecotoxicology       Date:  2016-02-29       Impact factor: 2.823

5.  n-Butanol extract of Rhynchosia volubilis Lour: a potent spermicidal agent In Vitro.

Authors:  Huang-Tao Guan; Fang Fang; Zhe Xiong; Tian-Qing Meng; Shi-Xing Huang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-06-18

6.  Ethical issues for late-stage trials of multipurpose prevention technologies for HIV and pregnancy.

Authors:  Jessica A Cohen; Anna C Mastroianni; Ruth Macklin
Journal:  Int J Gynaecol Obstet       Date:  2014-07-22       Impact factor: 3.561

7.  Influence of Menstrual Cycle and Oral Contraceptive Phase on Spinal Excitability.

Authors:  Ellen Casey; Maria Reese; Ezi Okafor; Danielle Chun; Christine Gagnon; Franz Nigl; Yasin Y Dhaher
Journal:  PM R       Date:  2016-02-10       Impact factor: 2.298

Review 8.  Pipeline for contraceptive development.

Authors:  Diana L Blithe
Journal:  Fertil Steril       Date:  2016-08-11       Impact factor: 7.329

9.  Rethinking progesterone regulation of female reproductive cyclicity.

Authors:  Kaiyu Kubota; Wei Cui; Pramod Dhakal; Michael W Wolfe; M A Karim Rumi; Jay L Vivian; Katherine F Roby; Michael J Soares
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-28       Impact factor: 11.205

10.  In situ-forming and pH-responsive hydrogel based on chitosan for vaginal delivery of therapeutic agents.

Authors:  Esmat Jalalvandi; Amin Shavandi
Journal:  J Mater Sci Mater Med       Date:  2018-10-22       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.